PARIS (Reuters) - Sanofi (>> Sanofi) said on Friday it remained committed to acquiring U.S. drug firm Medivation (>> Medivation Inc) and that it was ready to speak directly to its shareholders.

Medivation said earlier that its board rejected an unsolicited $9.3 billion (6.35 billion pounds) takeover proposal from Sanofi, saying the offer undervalued the company and its pipeline of cancer drugs.

"Sanofi is a disciplined acquirer and has a strong acquisition track-record," the French drugmaker said in a statement. "While to date Medivation has chosen not to enter into discussions regarding this value-creating transaction, Sanofi remains committed to the combination.

"Combining Sanofi and Medivation represents a compelling strategic and financial opportunity to drive immediate and certain value for Medivation's shareholders," it added.

(Reporting by Matthias Blamont; Editing by James Regan)

Stocks treated in this article : Sanofi, Medivation Inc
Stocks treated in this article : Medivation Inc, Sanofi, FIRM, ENTER